Objective: To study the effects of salmeterol fluticasone on lung function and airway hyperresponsiveness in patients with bronchial asthma in remission. Methods: A total of 80 patients with bronchial asthma in remission who were treated from July 2016 to July 2019 were randomly divided into an observation group and a control group, each with 40 cases. The control group was treated with fluticasone propionate inhalation, and the observation group was treated with salmeterol fluticasone powder. The treatment effects were compared between the two groups. Results: The total effective rate in the observation group (97.50%) was higher than that in the control group (82.50%), and the difference was statistically significant (P<0.05). After the treatment, the levels of lung function indicators such as FVC, FEV1, and PEF were higher than those before the treatment (P<0.05), and those in the observation group was higher than those in the control group (P<0.05). The positive rate of the challenge test in the two groups after the treatment were significantly lower than that before the treatment (P<0.05), and that in the observation group was lower than that in the control group (P<0.05). Conclusion: Salmeterol and roticasone treatment for patients with bronchial asthma in remission can effectively alleviate the clinical symptoms, and have significant relief effects on patients’ lung function and airway hyperresponsiveness.